

17 million traders 1 free Apple share* [Join waitlist](#) *T&Cs apply

Health & Biotech • Biotech



EZZ's big growth plans on target after another quarter, oodles of cash and expanding distribution

Health & Biotech

February 1, 2022 | Special Report

[SHARE](#) [f](#) [t](#) [in](#)

EZZ has reported a strong December quarter as it continues its transformation into a fully integrated life sciences company.

Innovative leader in the genomic-tech space EZZ Life Science Holdings (ASX:EZZ) has reported a solid cash position with a closing balance of \$8.9 million for Q2 FY22.

The cash was a very slight drop on Q1 FY22, because of EZZ's maiden dividend payout and carried over manufacturing costs.

Although the company was closed for three weeks over the Christmas break, cash received from customers remained strong for Q2, with an increase of ~\$80k compared to Q1 FY22.

EZZ's operating cash flows reduced in the quarter due to manufacturing cost payments and deposits to manufacturers and suppliers to increase production in the following months.

Maiden dividend payout and profitable

EZZ listed back in March 2021 after an oversubscribed public offering.

The company has already rewarded investors with a maiden, fully franked dividend of 0.45 cents per share.

The dividend represented a payout ratio of 7.5% based on the company's earnings per share of 5.98 cents, which increased by 13% throughout FY21.

New products

The company added two new products to its range in Q2 FY22. EZZ Biotic EnGastro Capsule and EZZ Biotic HHP Support Probiotic will help promote a healthy digestive system and immune system function, treat diarrhoea and reduce symptoms of medically diagnosed Irritable Bowel Syndrome (IBS).

The new EZZ branded Biotic products aim to target the bacterial balance in the gut and provide effective microbiome digestive support where imbalances can activate the immune system.

Both products also aim to combat Helicobacter Pylori, which is a common type of bacteria that grows in the digestive tract and tends to attack the stomach lining, causing stomach ulcers and increases the risk of stomach cancer.

Expanded product distribution

During the quarter, EZZ established four new distribution channels internationally in the USA, Singapore and China. The Chemist Warehouse China Flagship store had placed their first order in November.

The company also started to run new online stores for both its EZZ and Eaoron branded products.

The development of these distribution channels has contributed approximate~10% of total revenue.

Forefront of personalised medicine

EZZ has already begun leveraging its genomic research with leading local and international universities, along with product development to isolate and unpack four key areas of being alive including:

- Genetic longevity (the world has an aging population)
- Human papillomavirus (some 80% of sexually active adults have the virus)
- helicobacter pylori (a cause of stomach ulcers and gastric cancers)
- weight management (to improve overall health)

The company has also earmarked establishing a Good Manufacturing Practice (GMP) certified manufacturing facility in Australia or New Zealand to improve production efficiency.

New chairman

In December EZZ appointed former CEO and COO of AusBiotech (Australia's biotechnology organisation) Glenn Cross as its new chairman and non-executive director as it continues transformation into a fully integrated life science company.

Cross has more than 40 years' experience in the life science sector domestically and internationally, including ~20 in senior executive roles.

In recent years Cross has been involved in capital markets and general investment activities in Australia, Asia, and North America. He is a non-executive director of multiple private and public companies and investment funds.

This article was developed in collaboration with EZZ, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

- Subscribe to our daily newsletter
- Join our small cap Facebook group
- Follow us on Facebook or Twitter

READ MORE

- [BIOTECH](#) [HEALTH](#)

[SHARE](#) [f](#) [t](#) [in](#)

SUBSCRIBE

Get the latest Stockhead news delivered free to your inbox.

[SUBMIT](#)

It's free. Unsubscribe whenever you want.

[Read our privacy policy.](#)

You might be interested in

[Health & Biotech](#)
EZZ launching new hangover recovery & weight management products
 February 16, 2022 | Special Report

[Health & Biotech](#)
EZZ to focus on combating cancer-causing digestive tract bacteria
 January 25, 2022 | Special Report

[Health & Biotech](#)
Stock Insiders: Veteran biotech player joins EZZ on journey to fully integrated life sciences company
 January 18, 2022 | Oriël Morrison

Sponsored Video by: [Marketech](#)
 Online trading has evolved [Find out more](#)

[Dianomi](#)
 Video by [Dianomi](#)

Sponsored Financial Content

[Top cryptos that are trending right now](#)
 eToro

[Eerily Accurate COVID-Crash Predictor Has a New Warning for Us...](#)
 Fat Tail Investment Research

[Free Report: Lithium Set to Take Off Again in 2022](#)
 Money Morning

1. TOP 5 STOCKS TO BUY NOW
2. 10 STOCKS TO HOLD FOREVER
3. BEST BANK FOR A SAVINGS ACCOUNTS
4. ABANDONED HOMES FOR SALE
5. HIGH RETURN INVESTMENTS

Don't be the last to know
 Get the latest stock news and insights straight to your inbox.

 It's free. Unsubscribe whenever you want.
[SUBSCRIBE](#)

[Read our privacy policy](#)

Featured Companies

[ASX: EZZ](#)
 EZZ Life Science

Editor's Picks

[WHAT'S IN THE BOX?](#)
 War, rates and recession: We unpack everything with David Bassanese and T. Rowe Price

[Wolfram at the door: Why China has a tungsten fight on its hands](#)

[Confessions of a Day Trader: Once more unto the breach, dear friends, once more...](#)

[REPORT: Five ways the world of crypto will change in 2022](#)

[Tonight at eleven...](#)
 Gold Digger: War (what is it good for?)

05m

TRADERS